PD-1 Knockout Engineered T Cells for Metastatic Renal Cell Carcinoma.
A Dose-escalation Phase I Trial of PD-1 Knockout Engineered T Cells for the Treatment of Metastatic Renal Cell Carcinoma
研究概览
详细说明
研究类型
阶段
- 阶段1
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Pathologically verified stage IV Renal cancer with measurable lesions (On CT: longest diameter of tumoral lesion >=10 mm, shorted diameter of lymph node >=15 mm; measurable lesions should not have been irradiated)
- Progressed after all standard treatment
- Performance score: 0-1
- Expected life span: >= 6 months
- Toxicities from prior treatment has resolved. Washout period is 4 weeks for chemotherapy, and 2 weeks for targeted therapy
- Major organs function normally
- Women at pregnant ages should be under contraception
- Willing and able to provide informed consent
Exclusion Criteria:
- Pathology is mixed type
- Emergent treatment of tumor emergency is needed
- Poor vasculature
- Coagulopathy, or ongoing thrombolytics and/or anticoagulation
- Blood-borne infectious disease, e.g. hepatitis B
- History of mandatory custody because of psychosis or other psychological disease inappropriate for treatment deemed by treating physician
- With other immune diseases, or chronic use of immunosuppressants or steroids
- Compliance cannot be expected
- Other conditions requiring exclusion deemed by physician
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
实验性的:Test group
Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will be knocked out by CRISPR Cas9 in the laboratory (PD-1 Knockout T cells).
The lymphocytes will be selected and expanded ex vivo and infused back into patients.
Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v.
before cell infusion.
A total of 2 x 10^7/kg PD-1 Knockout T cells will be infused in one cycle.
Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third.Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit(IU)/Kg/ day (if tolerant).
Patients will receive a total of 2, 3, 4 cycles of treatment.
|
PD-1敲除T细胞和PD-1野生型T细胞将由赛尔生物有限公司生产。
2x107/kg T细胞将分别用于试验组和比较组。
环磷酰胺以 20mg/kg 单次剂量静脉内给药 3 天。 细胞输注前。 白细胞介素2(IL-2)将在接下来的5天内给予,720000国际单位(IU)/Kg/天(如果能耐受)。
其他名称:
白细胞介素2(IL-2)将在细胞输注后5天给予,720000国际单位(IU)/Kg/天(如果耐受)。
其他名称:
|
安慰剂比较:Comparable group
Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will not be knocked out by CRISPR Cas9 in the laboratory (PD-1 Wild-type T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients. Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion. A total of 2 x 10^7/kg PD-1 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third.Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit(IU)/Kg/ day (if tolerant). Patients will receive a total of 2, 3, 4 cycles of treatment. |
环磷酰胺以 20mg/kg 单次剂量静脉内给药 3 天。 细胞输注前。 白细胞介素2(IL-2)将在接下来的5天内给予,720000国际单位(IU)/Kg/天(如果能耐受)。
其他名称:
白细胞介素2(IL-2)将在细胞输注后5天给予,720000国际单位(IU)/Kg/天(如果耐受)。
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
---|---|
使用不良事件通用术语标准 (CTCAE v4.0) 以不良事件和/或剂量限制毒性作为衡量 PD-1 敲除 T 细胞剂量安全性和耐受性的参与者人数
大体时间:剂量递增 - 大约 6 个月
|
剂量递增 - 大约 6 个月
|
次要结果测量
结果测量 |
大体时间 |
---|---|
反应率:将根据 RECIST v1.1 评估反应
大体时间:90天
|
90天
|
无进展生存期 - PFS
大体时间:从随机化日期到首次记录到进展日期或任何原因死亡日期,以先到者为准,平均评估时间为 10 个月
|
从随机化日期到首次记录到进展日期或任何原因死亡日期,以先到者为准,平均评估时间为 10 个月
|
总生存期 - OS
大体时间:从随机分组到因任何原因死亡的时间,评估长达 2 年
|
从随机分组到因任何原因死亡的时间,评估长达 2 年
|
外周血循环肿瘤DNA
大体时间:6周
|
6周
|
外周血中白细胞介素-2 的暂时性变化
大体时间:基线和1个月和3个月
|
基线和1个月和3个月
|
外周血中干扰素-γ的时间变化
大体时间:基线和1个月和3个月
|
基线和1个月和3个月
|
外周血中白细胞介素6的时间变化
大体时间:基线和1个月和3个月
|
基线和1个月和3个月
|
合作者和调查者
出版物和有用的链接
一般刊物
- Yi L, Li J. CRISPR-Cas9 therapeutics in cancer: promising strategies and present challenges. Biochim Biophys Acta. 2016 Dec;1866(2):197-207. doi: 10.1016/j.bbcan.2016.09.002. Epub 2016 Sep 15.
- Gandini S, Massi D, Mandala M. PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2016 Apr;100:88-98. doi: 10.1016/j.critrevonc.2016.02.001. Epub 2016 Feb 10.
- Koshkin VS, Rini BI. Emerging therapeutics in refractory renal cell carcinoma. Expert Opin Pharmacother. 2016 Jun;17(9):1225-32. doi: 10.1080/14656566.2016.1182987. Epub 2016 May 23.
- Hofmann L, Forschner A, Loquai C, Goldinger SM, Zimmer L, Ugurel S, Schmidgen MI, Gutzmer R, Utikal JS, Goppner D, Hassel JC, Meier F, Tietze JK, Thomas I, Weishaupt C, Leverkus M, Wahl R, Dietrich U, Garbe C, Kirchberger MC, Eigentler T, Berking C, Gesierich A, Krackhardt AM, Schadendorf D, Schuler G, Dummer R, Heinzerling LM. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer. 2016 Jun;60:190-209. doi: 10.1016/j.ejca.2016.02.025. Epub 2016 Apr 13.
- Gunturi A, McDermott DF. Potential of new therapies like anti-PD1 in kidney cancer. Curr Treat Options Oncol. 2014 Mar;15(1):137-46. doi: 10.1007/s11864-013-0268-y.
- Bockorny B, Dasanu CA. Intrinsic immune alterations in renal cell carcinoma and emerging immunotherapeutic approaches. Expert Opin Biol Ther. 2013 Jun;13(6):911-25. doi: 10.1517/14712598.2013.778970. Epub 2013 Apr 16.
研究记录日期
研究主要日期
学习开始
初级完成 (预期的)
研究完成 (预期的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
PD-1 敲除 T 细胞的临床试验
-
The First Affiliated Hospital of Guangdong Pharmaceutical...Guangzhou Anjie Biomedical Technology Co., Ltd.未知
-
The First Affiliated Hospital of Guangdong Pharmaceutical...University of Technology, Sydney; Guangzhou Anjie Biomedical Technology Co., Ltd.未知
-
Mahmoud Ramadan mohamed Elkazzaz尚未招聘
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityGuangzhou Anjie Biomedical Technology Co., Ltd.完全的
-
Beijing YouAn HospitalBeijing Gene Key Life Technology Co., Ltd.招聘中
-
Shanghai Cell Therapy Research Institute未知
-
Shanghai Cell Therapy Research Institute未知
-
The First Affiliated Hospital of Soochow UniversityFundamenta Therapeutics, Ltd.招聘中